Lewy body pathology in Alzheimer's disease: A clinicopathological prospective study.
Alzheimer's disease
Lewy bodies
neuropsychology
pathology
Journal
Acta neurologica Scandinavica
ISSN: 1600-0404
Titre abrégé: Acta Neurol Scand
Pays: Denmark
ID NLM: 0370336
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
03
05
2018
revised:
04
09
2018
accepted:
13
09
2018
pubmed:
20
9
2018
medline:
31
1
2019
entrez:
20
9
2018
Statut:
ppublish
Résumé
Identify clinical features predictive of Lewy body pathology in Alzheimer's disease (AD) patients in an ongoing longitudinal clinicopathologic study. We queried the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND) database for dementia cases with AD pathology (1997-2015). Subjects received longitudinal comprehensive clinical evaluations including motor/neuropsychological assessment and Apo-E4 genotyping. All cases were autopsied and had standard neuropathological assessments for AD and Lewy-type synucleinopathy (LTS). Subjects were categorized based on standardized pathological criteria with AD cases that had LTS but did not meet DLB pathologic criteria being categorized as ADLB. We performed pairwise comparison between the different diagnoses and multivariable modelling to identify clinical symptoms that predict the pathological diagnosis. We identified 32 DLB/AD, 54 ADLB, 70 AD only and 41 PDD/AD cases. AD subjects with LTS pathology had higher UPDRS II and III total scores as well as generally higher individual scores compared to AD alone. While depression scales and Trail-making Test A correlated significantly with LTS, other neuropsychological variables were not significantly different. Apo E4 occurrence was similar in all groups (40%-49%). Our study suggests that the presence (or absence) of LTS influences motor and non-motor clinical findings in AD patients. These findings may lead to biomarkers that allow for more targeted treatment of AD.
Identifiants
pubmed: 30229861
doi: 10.1111/ane.13028
pmc: PMC6634943
mid: NIHMS1039980
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
76-81Subventions
Organisme : Neurocrine
Organisme : Biogen
Organisme : Acorda
Organisme : Michael J. Fox Foundation for Parkinson's Research
Organisme : Biotie
Organisme : Arizona Parkinson's Disease Consortium
Organisme : Arizona Biomedical Research Consortium
Organisme : Lilly
Organisme : CurePSP Foundation
Organisme : Axovant
Organisme : Takeda
Organisme : Arizona Biomedical Research Commission
ID : 4001
Organisme : Cynapsus/Sunovion
Organisme : National Institute on Aging
Organisme : USC-ALZ Association
Organisme : National Institute of Neurological Disorders and Stroke
ID : U24 NS072026
Organisme : Mayo Clinic Foundation
Organisme : Avid
Organisme : NIH
Organisme : Jazz Pharmaceuticals
Organisme : Henry M. Jackson Foundation and Daiichi Sankyo Co., Ltd.
Organisme : AstraZeneca
Organisme : Novartis
Organisme : Impax
Organisme : Arizona Biomedical Research Commission
ID : 1001
Organisme : Teva
Organisme : Suven
Organisme : National Brain and Tissue Resource for Parkinson's Disease and Related Disorders
ID : U24 NS072026
Organisme : US Department of Defense
Organisme : Abbvie
Organisme : Merck
Organisme : Navidea
Organisme : Arizona Biomedical Research Commission
ID : 05-901
Organisme : Neurocrine, Navidea
Organisme : Roche
Organisme : Intec
Organisme : Arizona Alzheimer's Disease Core Center
ID : P30 AG19610
Organisme : Pfizer
Organisme : US World Meds
Organisme : Arizona Department of Health Services
ID : 211002
Organisme : Pharma 2B
Organisme : Genentech
Organisme : National Institute of Neurological Disorders and Stroke
Organisme : NINDS NIH HHS
ID : U24 NS072026
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG019610
Pays : United States
Organisme : Arizona Biomedical Research Commission
ID : 0011
Organisme : National Institute on Aging
ID : P30 AG19610
Organisme : Alzheimer's Association
Organisme : Arizona Alzheimer's Consortium
Organisme : Eli Lily
Informations de copyright
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
J Neuropathol Exp Neurol. 1999 Nov;58(11):1147-55
pubmed: 10560657
Nat Med. 2004 Oct;10(10):1055-63
pubmed: 15459709
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
pubmed: 1564476
Neurology. 2005 Jun 28;64(12):2069-73
pubmed: 15985574
Neurology. 2005 Dec 27;65(12):1863-72
pubmed: 16237129
Neurology. 2005 Nov 22;65(10):1575-83
pubmed: 16301484
Clin Neuropsychol. 2006 Dec;20(4):623-36
pubmed: 16980250
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
Cell Tissue Bank. 2008 Sep;9(3):229-45
pubmed: 18347928
Acta Neuropathol. 2008 Sep;116(3):277-88
pubmed: 18626651
Acta Neuropathol. 2009 Jun;117(6):613-34
pubmed: 19399512
J Neurol. 2010 Mar;257(3):359-66
pubmed: 19795154
Neurology. 1991 Apr;41(4):479-86
pubmed: 2011243
Mov Disord. 2010 Apr 15;25(5):642-6
pubmed: 20175211
Alzheimers Dement. 2011 Jan;7(1):80-93
pubmed: 21255746
Ann Neurol. 2013 Sep;74(3):478-89
pubmed: 23798485
Neuropathology. 2015 Aug;35(4):354-89
pubmed: 25619230
JAMA Neurol. 2015 Jul;72(7):789-96
pubmed: 25985321
N Engl J Med. 2015 Aug 6;373(6):511-20
pubmed: 26095746
Neurobiol Aging. 1997 Jul-Aug;18(4 Suppl):S1-2
pubmed: 9330978